SD Life Sciences Roundup: Optimer, Illumina, & Deals, Deals, Deals
(Page 2 of 2)
raised $11.8 million in a Series B round of financing that included two new investors, the Redmile Group and Claremont Creek Ventures. Private investors from Genalyte’s Series A round also participated. The company says it plans to introduce its product this summer, initially addressing the autoimmunity research and testing markets.
—San Diego’s Tioga Pharmaceuticals, which is developing new drugs for treating gastrointestinal diseases, has raised $10 million from investors, according to a recent regulatory filing. On its website, Tioga says it was founded in 2005 by Forward Ventures and raised $24 million in Series A financing with New Leaf Venture Partners and BB Biotech Ventures.
—San Diego-based Adamis Pharmaceuticals has raised $3.3 million in equity, debt, and rights to securities, according to a recent regulatory filing. The company says it is combining specialty pharmaceuticals and biotechnology to develop innovative drugs in three areas, allergies, asthma, and respiratory diseases; cancer; and immunology and infectious diseases. The company was previously known as Cellegy Pharmaceuticals.
—San Diego-based Ocera Therapeutics has raised $1.5 million of a targeted $3 million in debt, rights, and securities, according to a recent regulatory filing. On its website, the company says CEO Laurent Fischer founded the company with Domain Associates partner Eckard Weber in 2005 to develop new drugs for treating liver and gastrointestinal diseases.